



Patent Application
Attorney Docket No. PC26968B

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for ~~TRADEMARKS~~, Box 1450, Alexandria, VA 22313-1450 on this 25th day of May, 2006.

By _____

Carol A. Senn
(Signature of person mailing)

Carol A. Senn
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KEVIN E. HENEGAR

APPLICATION NO.: 10/791,198

Examiner: Charanjit Aulakh

FILING DATE: MARCH 2, 2004

Group Art Unit: 1625

TITLE: COMPOUNDS USEFUL IN PREPARING :
CAMPTOTHECIN DERIVATIVES :

TERMINAL DISCLAIMER

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pharmacia Corporation is the owner of 100% interest in the above-captioned application; and in U.S. Patent No 6,723,729, issued April 20, 2004. Pharmacia Corporation hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of U. S. Patent No. 6,723,729, including any patent term extensions, restorations or adjustments for said patent available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,723,729. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such period that the legal title to it and to the above-identified granted patent shall be commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of

the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the above-identified grant patent, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the granted patent expires for failure to pay a maintenance fee, is held unenforceable and/or invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or its term is in any manner shortened prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

This Terminal Disclaimer is accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,



David L. Kershner, Ph.D.
Register No. 53,112
Attorney of Record

Date: May 25, 2006

Pfizer Inc Legal Department
150 East 42nd Street -- 5th Floor
New York, New York 10017-5612
(212) 733-0538



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number.

PTO/SB/17(01/03)
Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment (\$ 130.00)

Complete If Known	
Application Number	10/791,198
Filing Date	March 2, 2004
First Named Inventor	Kevin E. Henegar
Examiner Name	C. Aulakh
Art Unit	1625
Attorney Docket No.	PC26968B

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account:

Deposit Account Number **16-1445**

Deposit Account Name **Pfizer Inc**

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.


FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051	65
1052	50	2052	25
1053	130	1053	130
1812	2,520	1812	2,520
1804	920*	1804	920*
1805	1,840*	1805	1,840
1251	110	2251	55
1252	420	2252	210
1253	950	2253	475
1254	1,480	2254	740
1255	2,010	2255	1005
1401	330	2401	165
1402	330	2402	165
1403	290	2403	145
1451	1,510	1451	1,510
1452	110	2452	55
1453	1,330	2453	665
1501	1,330	2501	665
1502	400	2502	240
1503	640	2503	320
1460	130	1460	130
1807	50	1807	50
1801	770	2801	365
1806	180	1806	180
8021	40	8021	40
1809	770	2809	385
1810	770	2810	385
Other Fee (specify)		For each additional invention to be examined (37 CFR 1.129(b))	
		Terminal Disclaimer	130.00

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY				Complete (if Applicable)
Name (Printed/Type)	David L. Kershner	Signature		Reg. Number 53,112 Telephone (212) 733-0538